Results 101 to 110 of about 26,436 (212)

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source

Biliary Abnormality on Imaging During Lenvatinib Plus Hepatic Arterial Infusion Chemotherapy With Cisplatin for Hepatocellular Carcinoma: A Pilot Descriptive Study

Hepatology Research, EarlyView.
ABSTRACT Aim To evaluate the frequency, imaging characteristics, associated factors, and clinical significance of biliary abnormalities on imaging in patients receiving lenvatinib (LEN) plus cisplatin hepatic arterial infusion chemotherapy (HAIC) for hepatocellular carcinoma (HCC).
Hirohito Osanai, Kazuto Kozaka, Takashi Matsubara, Norihide Yoneda, Takahiro Ogi, Kenichiro Okumura, Atsushi Takamatsu, Azusa Kitao, Shintaro Yagi, Taro Yamashita, Satoshi Kobayashi   +10 more
wiley   +1 more source

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

, 2015
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study ...
Wirth, Lori J, Sherman, Steven I, Habra, Mouhammed Amir, Newbold, Kate, Shah, Manisha H, Robinson, Bruce, Brose, Marcia S, Gianoukakis, Andrew G, Kiyota, Naomi, Kim, Sung-Bae, de las Heras, Begoña, Taylor, Matthew H, Hoff, Ana O, Tahara, Makoto, Zhu, Junming, Schlumberger, Martin, Elisei, Rossella, Dutcus, Corina E, Krzyzanowska, Monika K   +18 more
core   +3 more sources

Combination Therapy of Transarterial Chemoembolization, Lenvatinib, and PD-1 Inhibitors Achieves Significant Tumor Response in Hepatocellular Carcinoma with Bile Duct Tumor Thrombus: A Case Report [PDF]

Yangkai Fu,1 Junyi Wu,1,2 Jiayi Wu,1,2 Yinan Li,1 Zhenxin Zeng,1 Deyi Liu,1 Han Li,1 Xiangye Ou,1 Zhongtai Lin,1 Shaoming Wei,1 Huachun Song,1 Maolin Yan1,2 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian Province, People’s
Yan M, Wu J, Li H, Li Y, Wei S, Zeng Z, Fu Y, Ou X, Lin Z, Liu D, Song H   +10 more
core  

Time to discontinuation of lenvatinib therapy.

, 2020
(A) Time to discontinuation of lenvatinib therapy of all patients. Median duration of LEN therapy was 6.6 months. (B) Time to discontinuation of lenvatinib therapy stratified by 4W-RDI. Patients with 4W-RDI ≥70% were able to continue LEN treatment longer
Shun Kaneko (8735283), Chiaki Maeyashiki (749428), Kaoru Tsuchiya (793697), Mao Okada (3897493), Kento Inada (8735286), Jun Itakura (554845), Masayuki Kurosaki (156560), Yuka Takahashi (172894), Kenta Takaura (1807024), Leona Osawa (8735289), Namiki Izumi (156627), Hiroyuki Nakanishi (698666), Shuhei Sekiguchi (8735292), Sakura Kirino (8735280), Yuka Hayakawa (675583), Wan Wang (354665), Yutaka Yasui (33074), Koji Yamashita (3063837), Yasuhiro Asahina (156563), Nobuharu Tamaki (793693), Mayu Higuchi (793694)   +20 more
core   +1 more source

Rapid Intrasegmental Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Incidence, Imaging Features, and Clinical Outcomes

Hepatology Research, EarlyView.
ABSTRACT Aim Radiofrequency ablation (RFA) is curative therapy for early‐stage hepatocellular carcinoma (HCC), but a rare subset of patients develop aggressive intrasegmental recurrence shortly after complete ablation. We characterized the incidence, risk factors, and absolute risk.
Takuma Kaneko, Takuma Nakatsuka, Ryosuke Tateishi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro   +8 more
wiley   +1 more source

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim The optimal treatment strategy for patients with intermediate‐stage hepatocellular carcinoma beyond the up‐to‐seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have ...
Keishi Ouchi, Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Atsushi Hiraoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Takayoshi Oikawa, Kei Endo, Tamami Abe, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi, Wataru Sato, Chikara Iino, Nobukazu Tanabe, Hiroshi Numao, Hiromasa Ohira, Hidekatsu Kuroda, Yoshiyuki Ueno, Atsushi Masamune   +22 more
wiley   +1 more source

Early Changes in Lymphocyte Counts Predict Clinical Outcomes in Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background Durvalumab plus tremelimumab (Dur/Tre) has shown promising efficacy in advanced hepatocellular carcinoma (HCC), but predictive biomarkers remain unclear. This study aimed to determine whether early changes in peripheral blood lymphocyte counts during Dur/Tre therapy can predict clinical outcomes.
Yuichi Honma, Shigeo Shimose, Takanori Ito, Issei Saeki, Joji Tani, Takanori Matsuura, Tetsu Tomonari, Yasuto Takeuchi, Nobuhito Taniki, Kyo Sasaki, Ryu Sasaki, Takeshi Hatanaka, Satoru Kakizaki, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Tomotake Shirono, Satoshi Itano, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Yuki Kanayama, Hisamitsu Miyaaki, Sohji Nishina, Nobuhiro Nakamoto, Motoyuki Otsuka, Tetsuji Takayama, Yuzo Kodama, Hideki Kobara, Taro Takami, Hiroki Kawashima, Takumi Kawaguchi, Masaru Harada, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group   +36 more
wiley   +1 more source

Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

JTO Clinical and Research Reports
Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC).
Masahiro Torasawa, MD, Tatsuya Yoshida, MD, PhD, Kouya Shiraishi, PhD, Naoko Goto, BS, Toshihide Ueno, PhD, Hitoshi Ichikawa, MD, PhD, Shigehiro Yagishita, MD, PhD, Shinji Kohsaka, MD, PhD, Yasushi Goto, MD, PhD, Yasushi Yatabe, MD, PhD, Akinobu Hamada, PhD, Hiroyuki Mano, MD, PhD, Yuichiro Ohe, MD, PhD   +12 more
doaj   +1 more source